Connection

ELIZABETH SHPALL to Cell Line, Tumor

This is a "connection" page, showing publications ELIZABETH SHPALL has written about Cell Line, Tumor.
Connection Strength

0.423
  1. Generation and testing of clinical-grade exosomes for pancreatic cancer. JCI Insight. 2018 04 19; 3(8).
    View in: PubMed
    Score: 0.052
  2. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One. 2013; 8(10):e76781.
    View in: PubMed
    Score: 0.038
  3. Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma. Cancer Res. 2011 Jul 15; 71(14):5040-9.
    View in: PubMed
    Score: 0.032
  4. CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3?/ZAP70 Signaling Axis. Cancer Discov. 2024 Oct 04; 14(10):1879-1900.
    View in: PubMed
    Score: 0.020
  5. Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD. Cancer Cell. 2024 Aug 12; 42(8):1450-1466.e11.
    View in: PubMed
    Score: 0.020
  6. Hu8F4-CAR T cells with mutated Fc spacer segment improve target specificity and mediate anti-leukemia activity in vivo. Cytotherapy. 2024 Nov; 26(11):1331-1340.
    View in: PubMed
    Score: 0.020
  7. Development of a rabbit human glioblastoma model for testing of endovascular selective intra-arterial infusion (ESIA) of novel stem cell-based therapeutics. Neuro Oncol. 2024 01 05; 26(1):127-136.
    View in: PubMed
    Score: 0.019
  8. Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells. Blood. 2023 09 21; 142(12):1056-1070.
    View in: PubMed
    Score: 0.019
  9. Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering. Sci Adv. 2023 07 28; 9(30):eadd6997.
    View in: PubMed
    Score: 0.019
  10. KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape. Nat Med. 2022 Oct; 28(10):2133-2144.
    View in: PubMed
    Score: 0.018
  11. GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK Cells. Front Immunol. 2021; 12:626098.
    View in: PubMed
    Score: 0.016
  12. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood. 2021 02 04; 137(5):624-636.
    View in: PubMed
    Score: 0.016
  13. Bone marrow stromal cells induce an ALDH+ stem cell-like phenotype and enhance therapy resistance in AML through a TGF-?-p38-ALDH2 pathway. PLoS One. 2020; 15(11):e0242809.
    View in: PubMed
    Score: 0.016
  14. Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-Specific Cytotoxic T Lymphocytes. Clin Cancer Res. 2019 04 15; 25(8):2610-2620.
    View in: PubMed
    Score: 0.014
  15. Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations. Genome Res. 2018 04; 28(4):432-447.
    View in: PubMed
    Score: 0.013
  16. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018 02; 32(2):520-531.
    View in: PubMed
    Score: 0.012
  17. Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-?B mediates chemoresistance. Blood. 2014 Apr 24; 123(17):2691-702.
    View in: PubMed
    Score: 0.010
  18. Conserved DNA methylation patterns in healthy blood cells and extensive changes in leukemia measured by a new quantitative technique. Epigenetics. 2012 Dec 01; 7(12):1368-78.
    View in: PubMed
    Score: 0.009
  19. Regulation of HIF-1a signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment. Cancer Biol Ther. 2012 Aug; 13(10):858-70.
    View in: PubMed
    Score: 0.009
  20. Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is associated with miR-210 and miR-155. Oncogene. 2012 Sep 13; 31(37):4085-94.
    View in: PubMed
    Score: 0.008
  21. Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104. PLoS One. 2011; 6(8):e23108.
    View in: PubMed
    Score: 0.008
  22. Clofarabine ? fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant. 2011 Jun; 17(6):893-900.
    View in: PubMed
    Score: 0.008
  23. piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther. 2010 Apr; 21(4):427-37.
    View in: PubMed
    Score: 0.007
  24. Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood. 2010 Apr 01; 115(13):2695-703.
    View in: PubMed
    Score: 0.007
  25. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res. 2008 Apr 15; 68(8):2961-71.
    View in: PubMed
    Score: 0.007
  26. Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells. Blood. 2006 Dec 15; 108(13):4071-7.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.